Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors–related AKI
Behandlungspraktiken und Outcomes bei Krebspatient:innen mit durch Immuncheckpoint-Inhibitoren bedingter AKI
Nephrology Dialysis Transplantation · 31.03.2026 · 41 (4) · 657-668
DOI: 10.1093/ndt/gfaf191 ↗Auf einen Blick
Bei 4 Jahren Nachbeobachtung traten unter ICI-Therapie AKI und schwere AKI auf; das AKI-Risiko war geringer als unter nicht-ICI-Systemtherapie. Re-Exposition war selten.
Fragestellung
Wie häufig tritt AKI bei Krebspatient:innen unter ICI-Therapie auf, welche Faktoren sind damit verbunden und wie sind Re-Exposition und Überleben nach AKI?
Methode
Beobachtungsstudie in Ontario, Kanada, 2012–18; Vergleich von ICI- und nicht-ICI-Systemtherapie; Zeit-zu-Ereignis-Modelle für AKI, Risikofaktoren und Überleben.
Ergebnisse
Unter 4 Jahren betrug die rohe AKI-Inzidenz bei 4380 Patient:innen mit ICI 29 %; schwere AKI (Stadium ≥2) 7 %. Das AKI-Risiko war unter ICI niedriger als unter nicht-ICI-Therapie (aHR 0,80; 95 %-KI 0,74–0,86).
Schlussfolgerung der Autor:innen
Die Studie zeigt ein moderates Risiko für schwere AKI unter ICI, geringer als bei anderen systemischen Krebstherapien. Nach AKI war eine Re-Exposition selten, könnte aber bei ausgewählten Patient:innen erwogen werden.
Kernaussagen
- AKI unter ICI: 29 % innerhalb von 4 Jahren
- Schwere AKI (Stadium ≥2): 7 %
- Re-Challenge nach AKI selten; 24 von 54 hatten erneut AKI
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 27.09.2025. Verfasst von Phillip S Blanchette und 7 weiteren Autor:innen. Beteiligte Einrichtung: ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre, London, Ontario, Canada. Hauptthemen laut MEDLINE: Acute Kidney Injury, Immune Checkpoint Inhibitors, Neoplasms, Practice Patterns, Physicians'. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Oncology Research Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Acute kidney injury (AKI) is a known immune-related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further population-based data on AKI incidence, risk factors and practice patterns post-ICI therapy are needed.
Methods
We measured the cumulative incidence of AKI among advanced cancer patients while receiving ICI therapy and non-ICI systemic therapy in Ontario, Canada (2012–18). An increase in serum creatinine was used to define AKI and graded according to event severity. Time to event modeling was used to compare the risk of developing AKI, pre-disposing factors and survival outcomes.
Results
We studied 16 425 patients with advanced cancer receiving either ICI or non-ICI systemic therapy. Among 4380 patients receiving ICI therapy, the overall crude 4-year incidence of AKI (any stage) was 29% and severe AKI (stage ≥2) was 7%. Characteristics associated with a higher risk of AKI included male sex, genitourinary (versus other) malignancy, the presence of hypertension, diabetes or chronic kidney disease, and prescription of a non-steroidal anti-inflammatory drug. The risk of experiencing AKI was significantly lower among patients treated with ICI versus non-ICI systemic therapy [adjusted hazards ratio (aHR) 0.80, 95% confidence interval (CI) 0.74–0.86, P-value <.0001]. Among the 587 patients who experienced an AKI and were both alive and discontinued ICI therapy within 30 days, 54 (9%) were re-challenged with ICI in the following 6 months and 24 (44%) had a recurrent AKI event. Patients who were re-challenged with ICI therapy had improved overall survival as compared with patients that received other non-ICI systemic therapy (aHR 0.38, 95% CI 0.22–0.67, P-value <.001).
Conclusion
Our real-world study demonstrates a modest risk for severe AKI among cancer patients receiving ICI therapy, lower than with exposure to other systemic cancer therapies. Among patients who developed AKI and stopped ICI therapy, re-challenge was uncommon but may warrant consideration for select patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre, London, Ontario, Canada.
- London Health Sciences Centre, London, Ontario, Canada.
- Division of Medical Oncology, Department of Oncology, Verspeeten Family Cancer Centre, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
- Current affiliation: MAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Ontario, Canada.
- Arthur Labatt Family School of Nursing, Western University, London, Canada.
- Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
ORCID-Profile: Phillip S Blanchette, Lucie Richard, Jacques Raphael, Abhijat Kitchlu
Förderung
- Medical Oncology Research Fund
Zitieren
APA
Blanchette, P. S., Reid, J., Richard, L., Shariff, S. Z., Raphael, J., Earle, C. C., Garg, A. X., & Kitchlu, A. (2026). Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors–related AKI. Nephrology Dialysis Transplantation, 41(4), 657-668. https://doi.org/10.1093/ndt/gfaf191
Vancouver
Blanchette PS, Reid J, Richard L, Shariff SZ, Raphael J, Earle CC, et al. Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors–related AKI. Nephrology Dialysis Transplantation. 2026;41(4):657-668. doi:10.1093/ndt/gfaf191
BibTeX
@article{Blanchette2026,
author = {Blanchette, Phillip S and Reid, Jennifer and Richard, Lucie and Shariff, Salimah Z and Raphael, Jacques and Earle, Craig C and Garg, Amit X and Kitchlu, Abhijat},
title = {Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors–related AKI},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {4},
pages = {657--668},
doi = {10.1093/ndt/gfaf191}
}
EUVIMED